End-to-End Continuous Manufacturing of Pharmaceuticals: Integrated Synthesis, Purification, and Final Dosage Formation

被引：479

作者：

Mascia, Salvatore ^{[1
]}

Heider, Patrick L. ^{[1
]}

Zhang, Haitao ^{[1
]}

Lakerveld, Richard ^{[1
]}

Benyahia, Brahim ^{[1
]}

Barton, Paul I. ^{[1
]}

Braatz, Richard D. ^{[1
]}

Cooney, Charles L. ^{[1
]}

Evans, James M. B. ^{[1
]}

Jamison, Timothy F. ^{[2
]}

Jensen, Klavs F. ^{[1
]}

Myerson, Allan S. ^{[1
]}

Trout, Bernhardt L. ^{[1
]}

机构：

[1] MIT, Dept Chem Engn, Cambridge, MA 02139 USA

[2] MIT, Dept Chem, Cambridge, MA 02139 USA

来源：

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION | 2013年 / 52卷 / 47期

关键词：

continuous processing; flow chemistry; lactones; protecting groups; synthetic methods; RENIN INHIBITOR; CONVERGENT SYNTHESIS; MICROREACTOR TECHNOLOGY; MIXED-SUSPENSION; FLOW; DESIGN; INTERMEDIATE; REVOLUTION; EXTRUSION; OPERATION;

D O I：

10.1002/anie.201305429

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

A series of tubes: The continuous manufacture of a finished drug product starting from chemical intermediates is reported. The continuous pilot-scale plant used a novel route that incorporated many advantages of continuous-flow processes to produce active pharmaceutical ingredients and the drug product in one integrated system. Copyright © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

引用

页码：12359 / 12363

页数：5

共 64 条

[1]

[Anonymous], 2011, US PHARMACOPEIAL 711

[2]

[Anonymous], 2011, US PHARMACOPEIAL 905

[3]

[Anonymous], 2006, INT C HARM Q3B R2

[4]

[Anonymous], 2011, INT C HARM Q3C R5